The global metagenomic sequencing market size was valued at USD 2582.8 million in 2025 and is projected to grow from USD 3034.79 million in 2026 to USD 11026.35 million by 2034, registering a CAGR of 17.5% during the forecast period from 2026 to 2034. North America dominated the metagenomic sequencing market with a market share of 42.5% in 2025.
Metagenomics is a biological approach in genomics that analyzes mixed genomic materials derived from a community of organisms using metagenomic sequencing. This approach gives detailed information on species diversity and abundance, functional genes, evolutionary relationships, population structure, and environmental factor correlation networks. Although these processes were developed for clinical diagnostics, drug discovery, biofuel, and industrial applications, they are now being employed for other purposes. Metagenomics allows researchers to study creatures difficult to culture in the lab because most microbes have never been cultured.
Download a Free Sample To learn more about this report,
Pathogen-Agnostic Sequencing Is Moving Into Broader Public Health Surveillance
The metagenomic sequencing market is shifting toward pathogen-agnostic surveillance that can identify many microorganisms from a single sample without selecting specific targets beforehand. Unlike targeted PCR assays, metagenomic approaches analyze genetic material broadly, making them useful when the responsible pathogen is unknown, unexpected, or newly emerging. Public health laboratories are evaluating this capability for respiratory surveillance, outbreak investigations, zoonotic spillover detection, and environmental monitoring. The approach can also reduce dependence on separate assays for individual organisms. As adoption develops, rapid sequencing, automated sample preparation, broad pathogen databases, and integrated bioinformatics are becoming important competitive capabilities for sequencing platforms serving infectious disease surveillance and preparedness programs.
in September 2025, WHO highlighted growing country interest in direct DNA/RNA metagenomic sequencing as a single, culture-independent approach for detecting and characterizing emerging and re-emerging pathogens.
Pandemic Preparedness Programs Are Expanding Demand for Genomic Surveillance Capacity
Government and public health efforts to strengthen preparedness for future outbreaks are increasing demand for sequencing and metagenomic capabilities. Genomic surveillance allows laboratories to identify pathogens, characterize genetic changes, investigate transmission, and provide information that supports public health decisions. Metagenomics extends this capability by examining diverse genetic material without requiring a predefined pathogen target, making it useful when unusual infections or unknown outbreak causes emerge. Building this capacity requires sequencing instruments, reagents, sample-processing technologies, bioinformatics software, databases, and trained personnel. As countries integrate genomics into routine disease surveillance rather than reserving it for emergencies, sustained investment in laboratory infrastructure can create recurring demand across the metagenomic sequencing ecosystem.
in 2025, WHO continued its global genomic surveillance strategy with the target that all 194 Member States should have timely access to pathogen genomic sequencing by 2032.
High Bioinformatics Requirements Limit Adoption in Resource-Constrained Laboratories
Metagenomic sequencing produces complex datasets that require substantial computing, storage, specialized software, curated reference databases, and trained bioinformatics professionals. Generating sequence reads is only one part of the workflow because laboratories must remove host sequences, identify organisms, assess contamination, interpret uncertain findings, and translate results into clinically or epidemiologically useful information. Smaller laboratories may lack the computing infrastructure and specialist workforce required to manage these processes reliably. Expanding sequencing capacity without matching investment in data analysis can therefore limit the practical value of metagenomic systems. These requirements increase implementation costs and can slow adoption in regions where laboratory budgets and genomic expertise remain limited despite growing interest in pathogen surveillance.
in July 2025, WHO established pathogen genomics communities of practice and noted that expanding genomic sequencing in public health laboratories requires a parallel increase in bioinformatics capacity to store, process, share, and integrate genomic data.
Wastewater Metagenomics Creates New Opportunities for Population-Level Pathogen Monitoring
Wastewater surveillance creates an opportunity for metagenomic sequencing because a single community sample can contain genetic material from many microorganisms circulating within the population. Instead of testing wastewater only for predefined pathogens, shotgun metagenomic approaches can screen broadly and potentially identify changes in microbial abundance before conventional case-reporting systems detect an outbreak. This capability can support monitoring of enteric infections, emerging pathogens, and other community-level health threats. Sequencing providers can benefit from demand for high-throughput instruments, long-read technologies, environmental sample preparation, analytical software, and automated pathogen identification. Combining metagenomics with epidemiological information could further expand its role as an early-warning component of public health surveillance systems.
in December 2025, researchers reported using high-throughput long-read metagenomic sequencing of communal wastewater in Quebec City, Canada, to monitor non-typhoidal Salmonella, with abundance increases detectable weeks before initial case reports.
Protocol Variation Makes Clinical Validation and Standardization Difficult
Standardizing metagenomic sequencing remains challenging because results can change according to sample type, extraction method, library preparation, sequencing platform, read depth, reference database, and bioinformatics pipeline. Clinical laboratories need consistent performance before results can guide diagnosis or treatment, especially when sequencing identifies organisms at very low abundance. Contamination from reagents or the environment can also create misleading signals, while incomplete reference databases may complicate organism classification. Laboratories must therefore establish quality controls, analytical thresholds, validation procedures, and interpretation standards for different applications. Without greater harmonization, results generated by separate laboratories may not always be directly comparable, limiting routine clinical implementation despite the technology's broad pathogen-detection capabilities.
in August 2025, a clinical metagenomics review emphasized that validation and accreditation of sequencing protocols remain necessary before metagenomic testing can become routine in clinical and public health laboratories.
Services is Projected to Register the Fastest Growth at a CAGR of 19.3%
The services segment is projected to register the fastest growth in the metagenomic sequencing market at a CAGR of 19.3% during the forecast period, driven by increasing demand for specialized sequencing, bioinformatics, data interpretation, and microbial analysis services. Research organizations, pharmaceutical companies, and healthcare institutions are increasingly outsourcing complex metagenomic workflows to specialized service providers. Growing sequencing data volumes, expanding microbiome research, and the need for advanced computational expertise continue to strengthen demand for metagenomic sequencing services.
Request Customizationto receive a tailored report.
Metatranscriptomic is Projected to Register the Fastest Growth at a CAGR of 20.2%
The metatranscriptomic segment is projected to register the fastest growth in the metagenomic sequencing market at a CAGR of 20.2% during the forecast period, supported by increasing research focused on understanding active microbial functions and gene expression within complex biological communities. Metatranscriptomic approaches enable researchers to investigate microbial activity beyond identifying organisms alone. Expanding microbiome studies, disease research, environmental analysis, and improvements in sequencing and bioinformatics technologies are supporting wider adoption of this approach.
Clinical Diagnostics is Projected to Register the Fastest Growth at a CAGR of 20.4%
The clinical diagnostics segment is projected to register the fastest growth in the metagenomic sequencing market at a CAGR of 20.4% during the forecast period, driven by increasing interest in sequencing-based approaches for identifying pathogens and characterizing complex microbial communities in clinical samples. Metagenomic sequencing can enable broad detection without requiring a predefined target, supporting research into infectious diseases and difficult-to-identify microorganisms. Advances in sequencing accuracy, bioinformatics, and clinical microbial analysis continue to support the development of metagenomics for diagnostic applications.
Speak to an Analystto discuss market opportunities.
North America dominated the metagenomic sequencing market with the largest 42.5% market share in 2025, representing a market value of USD 1.1 billion. The region is projected to grow at a CAGR of 16.9% during the forecast period. Its leadership is supported by advanced genomic research capabilities, extensive sequencing infrastructure, and increasing use of metagenomics across clinical research, infectious disease studies, microbiome analysis, environmental monitoring, and biotechnology. Research institutions and laboratories are adopting high-throughput sequencing and sophisticated bioinformatics platforms to analyze complex microbial communities. Continued investment in genomics, precision medicine, sequencing technologies, and computational biology strengthens North America’s position in the global metagenomic sequencing market.
The United States remains the primary contributor to the metagenomic sequencing market in North America due to its extensive genomics ecosystem and strong concentration of biotechnology companies, sequencing laboratories, academic institutions, and healthcare research organizations. Metagenomic sequencing is increasingly used to investigate microbial communities without requiring traditional culture-based approaches, supporting applications across infectious disease research, microbiome studies, environmental science, and drug discovery. Improvements in sequencing platforms and computational analysis are making complex microbial datasets more accessible to researchers. Growing integration of artificial intelligence and bioinformatics with genomic workflows is further improving analytical capabilities. Continued research investment supports long-term development of the country's metagenomic sequencing market.
Canada is strengthening its position in the metagenomic sequencing market through growing genomics research, biotechnology development, and increasing application of advanced sequencing technologies. Universities, research institutes, healthcare laboratories, and environmental organizations are exploring microbial communities across human health, agriculture, water systems, ecosystems, and other research areas. Increasing availability of high-throughput sequencing platforms and advanced bioinformatics tools is supporting more detailed analysis of complex biological samples. Collaboration between academic researchers, healthcare organizations, and biotechnology companies is also encouraging broader adoption. Continued development of genomics infrastructure and computational biology capabilities supports expansion of Canada's metagenomic sequencing market.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is the fastest-growing region in the metagenomic sequencing market and is expected to expand at a CAGR of 20.6% during the forecast period. The region accounted for 21.8% of the global market in 2025, representing a market value of USD 0.56 billion. Growth is supported by expanding genomics research, improving sequencing infrastructure, and increasing investment in biotechnology and precision medicine. Metagenomic approaches are gaining applications across microbiome research, infectious disease analysis, agriculture, environmental monitoring, and pharmaceutical research. Increasing availability of sequencing technologies and bioinformatics capabilities, combined with growing scientific research activity, supports strong expansion of the metagenomic sequencing market across Asia Pacific.
Japan is an important contributor to the metagenomic sequencing market due to its advanced biotechnology industry, strong biomedical research environment, and established capabilities in genomic science. Researchers are applying metagenomic approaches to investigate microbial communities associated with human health, food, agriculture, environmental systems, and other biological environments. Development of sophisticated sequencing platforms and computational analysis methods is improving the ability to process complex genomic information. Integration of microbiome research with healthcare and pharmaceutical development is creating additional opportunities for advanced sequencing applications. Continued investment in life sciences, genomic research, and data-driven biological analysis strengthens Japan's contribution to the Asia Pacific metagenomic sequencing market.
China plays a significant role in the metagenomic sequencing market through its expanding genomics infrastructure and increasing investment in biotechnology, healthcare research, and life sciences. Research institutions and laboratories are using metagenomic sequencing to study microbial populations across clinical, agricultural, environmental, and industrial applications. Growing sequencing capacity and development of bioinformatics platforms are enabling researchers to analyze increasingly large and complex datasets. Expanding microbiome research and interest in precision medicine are also creating opportunities for metagenomic technologies. Continued development of domestic sequencing capabilities, computational biology, and biotechnology research reinforces China's importance within the Asia Pacific metagenomic sequencing market.
Europe accounted for 27.3% of the global metagenomic sequencing market in 2025, reaching a market value of USD 0.71 billion. The region is anticipated to grow at a CAGR of 16.4% during the forecast period. Market development is supported by advanced life science research, increasing microbiome studies, and growing adoption of next-generation sequencing technologies. Academic institutions, healthcare researchers, biotechnology companies, and environmental organizations are using metagenomic sequencing to analyze complex microbial communities. Increasing availability of sophisticated bioinformatics tools and high-throughput sequencing infrastructure is expanding potential applications. Continued investment in genomics and biomedical research supports expansion of the metagenomic sequencing market across Europe.
Germany is an important contributor to the metagenomic sequencing market in Europe due to its advanced biotechnology, pharmaceutical, healthcare research, and life science industries. Universities and research organizations are using sequencing technologies to study microbial diversity and understand interactions within complex biological systems. Metagenomic approaches provide opportunities across microbiome research, infectious disease studies, environmental analysis, food science, and pharmaceutical development. Strong capabilities in laboratory technologies, bioinformatics, and scientific research provide a supportive environment for advanced genomic applications. Continued collaboration among academic institutions, biotechnology companies, and healthcare organizations strengthens Germany's position within the European metagenomic sequencing market.
The United Kingdom is a significant contributor to the metagenomic sequencing market through its established genomics research ecosystem and strong capabilities in biomedical science and bioinformatics. Researchers are applying metagenomic technologies to study microbial communities across human health, infectious diseases, environmental systems, agriculture, and other areas. Integration of advanced sequencing with computational biology enables laboratories to process complex microbial information and identify patterns that conventional methods may not easily reveal. Growing collaboration between universities, healthcare research organizations, and biotechnology companies supports broader adoption. Continued development of genomic technologies strengthens the United Kingdom's contribution to the European metagenomic sequencing market.
Latin America represented 5.1% of the global metagenomic sequencing market in 2025, with a market value of USD 0.13 billion. The region is expected to register a CAGR of 15.8% during the forecast period. Growth is supported by expanding genomic research, increasing biotechnology capabilities, and growing interest in microbial analysis across healthcare, agriculture, and environmental science. Research organizations are increasingly exploring sequencing-based approaches to understand complex microbial ecosystems. Improvements in laboratory infrastructure and bioinformatics capabilities are creating additional opportunities for adoption. Continued investment in life science research and genomic technologies supports expansion of the regional metagenomic sequencing market.
Brazil is an important contributor to the metagenomic sequencing market in Latin America due to its extensive biodiversity, agricultural sector, healthcare research ecosystem, and growing genomics capabilities. Researchers can apply metagenomic sequencing to investigate microbial communities associated with soils, crops, water systems, ecosystems, infectious diseases, and human health. Universities and research organizations are developing expertise in sequencing technologies and computational analysis to support increasingly sophisticated biological studies. Growing biotechnology activity is also expanding opportunities for microbial research and genomic applications. Continued development of laboratory infrastructure and bioinformatics expertise reinforces Brazil's importance within the regional metagenomic sequencing market.
The Middle East and Africa accounted for 3.3% of the global metagenomic sequencing market in 2025, representing a market value of USD 0.09 billion. The region is projected to expand at a CAGR of 14.9% during the forecast period. Market development is supported by increasing investment in genomic research, healthcare infrastructure, and biotechnology capabilities. Metagenomic sequencing offers applications across infectious disease research, environmental monitoring, agriculture, microbiome studies, and public health research. Improvements in sequencing infrastructure and computational capabilities are supporting wider scientific adoption. Continued development of life science research capabilities supports the long-term expansion of the metagenomic sequencing market across the region.
The UAE is an emerging contributor to the metagenomic sequencing market within the Middle East and Africa due to its increasing focus on genomics, precision medicine, biotechnology, and advanced healthcare research. Research organizations and laboratories can apply metagenomic sequencing to microbiome studies, infectious disease analysis, environmental monitoring, and other biological research applications. Growing investment in genomic infrastructure and data-driven healthcare creates a supportive environment for sophisticated sequencing technologies. Development of bioinformatics capabilities is also important for interpreting complex microbial datasets generated through metagenomic approaches. Continued investment in life sciences and advanced research strengthens the UAE's role in the regional metagenomic sequencing market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com